Compare CSX Corporation (CSX) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Halozyme Therapeutics Inc. Common Stock — how do they compare? CSX Corporation trades at $47.3 (market cap $87.70B), while Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B). The key difference: CSX Corporation is far larger — about 7× Halozyme Therapeutics Inc. Common Stock's market cap, and CSX Corporation pays a 1.18% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| CSX | HALO | |
|---|---|---|
Market Cap | $87.70B | $12.58B |
Volume | 6,980,781 | 2,179,278 |
Sector | Industrials | Health |
52-Week High | $53.21 | $115.22 |
52-Week Low | $33.68 | $61.63 |
Typical Hold Time | 55 Days | 1 Days |
Enterprise Value | $105.66B | $14.49B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.26, up 0.96% with a bullish technical signal. The stock shows strong profitability with 22.21% net margin and 24.37% ROE, though revenue declined to $14.09B in 2025. Recent Q2 2026 earnings beat expectations at $0.54 vs $0.518. Analyst consensus is bullish with 58.69% buy ratings and $51.00 price target. The company maintains stable cash flow operations and recently announced a $0.14 dividend payable September 2026.
CSX presents a favorable investment case with strong fundamentals and analyst support, though valuation metrics appear elevated. Key risks include revenue pressure and competitive threats. The upcoming Q3 2026 earnings on October 21 will be critical for confirming the positive trend. Current levels offer potential upside to consensus targets but require monitoring of operational execution.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
